BPC-157 supplied ready to use in a metered intranasal bottle — the same pentadecapeptide, with the reconstitution variable removed.
- Contains
- BPC-157 (sequence, formula and CAS number are on the vial product page)
- Content
- 15mg in a metered 15ml bottle
- Presentation
- ready-to-use metered intranasal solution; no reconstitution step
- Purity
- ≥99% by HPLC, identity confirmed by mass spectrometry
- Released against
- the Certificate of Analysis for its own batch
About BPC-157 Nasal Spray
This is BPC-157 — the fifteen-residue fragment of body protection compound, sequence GEPPPGKPADDAGLV — supplied in solution in a metered 15ml intranasal bottle rather than as a lyophilised cake.
The compound is identical to the vial presentation. What differs is that the concentration is already fixed and verified, which removes reconstitution as a source of error between one experiment and the next. For protocols comparing results across sites or across time, that consistency is the reason to choose this format.
What the research covers
The research context is the same as for the vial: angiogenic signalling through VEGFR2, gastrointestinal mucosal endpoints, and tendon, ligament and muscle models. The BPC-157 page covers the literature and its limits.
Where the intranasal route is itself part of the design, this presentation is the relevant one; where it is not, the vial gives control over concentration that a fixed preparation cannot. The tissue repair research peptides hub sets out the mechanisms in this group.
Handling BPC-157 Nasal Spray
Supplied as a metered intranasal preparation, so there is no reconstitution step and no opportunity for a reconstitution error — the concentration is fixed at what is supplied, which removes one variable and forecloses another.
Keep the bottle cold and upright, protect from light, and note that a peptide already in aqueous solution has a shorter usable life than a sealed lyophilised vial — this format trades long-term stability for immediate usability.
Other formats
The same compound is supplied as a lyophilised BPC-157 vial, which gives control over concentration that a fixed solution cannot.
Common questions about BPC-157 Nasal Spray
Is this the same compound as the BPC-157 vial?
Yes. The compound is identical; it is supplied already in solution in a metered intranasal bottle instead of as a lyophilised powder.
When is the nasal spray the better choice?
When the intranasal route is itself part of the study design, or when consistency between sessions matters more than control over concentration.
When is the vial the better choice?
When the protocol needs to set its own concentration or run dose-ranging. A fixed-concentration solution cannot be varied.
How long does the spray remain usable?
A peptide in solution has a shorter usable life than a sealed lyophilised vial. Keep the bottle cold, upright and protected from light, and treat its life as limited.
